Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
| 対象疾患 | Smoldering Plasma Cell Myeloma |
|---|---|
| 相 | 第1相前期 |
| スポンサー | M.D. Anderson Cancer Center |
| ステータス | 実施中（募集終了） |
| 参加者数 | 20 名 |
| 介入（薬剤） | Laboratory Biomarker Analysis, Pembrolizumab |
| 開始日 | 2016年7月20日 |
| 完了日 | 2017年12月30日 |
| 結果公開日 | 2020年3月20日 |
概要
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Overall Response Rate (ORR)
| Treatment (Pembrolizumab) | 1 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) a — University of Alabama at Birmingham
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (M — National Cancer Institute (NCI)